ImmunisAI
Click to visit website
About
Immunis.AI is a privately held immunogenomics company focused on developing liquid biopsy solutions for early-stage disease detection and monitoring. The company provides a platform that integrates immune system analysis with machine learning to offer actionable insights for patients and healthcare providers. By focusing on how the body's defense mechanisms react to disease, the technology aims to identify biological signals earlier than traditional diagnostic methods, facilitating more proactive disease management and surveillance. The operational core of the technology is a patented platform originally developed at Harvard Medical School. It functions by isolating specific immune cells from a patient's blood sample and analyzing their gene expression patterns. The system applies proprietary AI algorithms to perform a "subtraction" of gene expression between two different immune cell types. This process normalizes the data against the patient's own baseline, effectively filtering out biological noise to enhance the relevant disease signal. This individualized approach allows for precise characterization of a patient's health status in real-time. This tool is primarily intended for use by physicians and patients who require frequent or early monitoring of chronic conditions, such as oncology. It serves as a critical component in "active surveillance" programs, where healthcare providers monitor a disease closely to determine if or when treatment is necessary. Because the process relies on a standard blood draw rather than invasive tissue sampling, it is suitable for longitudinal studies and regular patient check-ups within a clinical workflow. What sets Immunis.AI apart from other diagnostic companies is its focus on immunogenomics rather than circulating tumor DNA or general biomarkers. By leveraging the sensitivity of the immune system, the platform can potentially detect disease changes before they are visible on traditional imaging. Additionally, the company operates its own clinical laboratory in Royal Oak, Michigan, which is certified by the Clinical Laboratory Improvement Amendments (CLIA) and accredited by the College of American Pathologists (CAP). This ensures that the AI-driven analytical results are produced within a regulated clinical environment.
Pros & Cons
Utilizes a unique cell-subtraction method to filter biological noise and enhance disease signals.
Technology is backed by a patented platform originally developed at Harvard Medical School.
Laboratory is fully CLIA-certified and CAP-accredited for clinical-grade reliability.
Provides a non-invasive liquid biopsy alternative for real-time disease monitoring.
Supports early detection and active surveillance across a robust pipeline of assays.
Specific pricing and insurance coverage details are not publicly listed on the website.
The platform is currently focused on specific medical assays rather than general-purpose genomic testing.
Usage is restricted to clinical settings and requires physician involvement.
Use Cases
Physicians can implement active surveillance for patients by using liquid biopsy to monitor disease progression without invasive surgery.
Oncology patients can receive highly individualized health assessments based on how their specific immune system is responding to a disease.
Clinical diagnostic teams can utilize the Harvard-developed algorithms to detect early-stage disease signals that might be missed by traditional imaging.
Platform
Features
• real-time active surveillance
• individualized patient assessments
• cap-accredited testing standards
• clia-certified clinical laboratory
• early-stage disease characterization
• patented immunogenomics platform
• ai-driven gene expression subtraction
• liquid biopsy pipeline
FAQs
How does the Immunis.AI platform analyze samples?
The platform uses proprietary AI algorithms to compare gene expression patterns between two specific types of immune cells isolated from blood. This subtraction method normalizes the data to enhance the biological signal for a personalized assessment.
What clinical certifications does the laboratory hold?
The Immunis.AI laboratory located in Royal Oak, Michigan, is certified by the Clinical Laboratory Improvement Amendments (CLIA). It is also accredited by the College of American Pathologists (CAP) to ensure high standards of testing.
What is the primary benefit of the liquid biopsy pipeline?
It provides a revolutionary solution for real-time active surveillance and early detection assays. This allows physicians and patients to access actionable information for disease management without necessarily requiring invasive procedures.
Where was the technology behind Immunis.AI developed?
The patented platform was originally created at Harvard Medical School. It has since been expanded into a robust intellectual property portfolio that protects both the core platform and specific assays.
Pricing Plans
Clinical Solutions
Unknown Price• Liquid biopsy analysis
• AI-driven gene expression subtraction
• CLIA-certified lab processing
• CAP-accredited reporting
• Real-time active surveillance
• Early detection assays
• Personalized disease characterization
Job Opportunities
There are currently no job postings for this AI tool.
Ratings & Reviews
No ratings available yet. Be the first to rate this tool!
Alternatives
Third Opinion
Improve diagnostic accuracy and patient safety with AI-powered medical image analysis and video monitoring designed for healthcare providers and radiologists.
View DetailsFeatured Tools
adly.news
Connect with engaged niche audiences or monetize your subscriber base through an automated marketplace featuring verified metrics and secure Stripe payments.
View Details
Image to Image AI
Transform photos and videos using advanced AI models for face swapping, restoration, and style transfer. Perfect for creators needing fast, professional visuals.
View Details
Nano Banana
Edit and enhance photos using natural language prompts while maintaining character consistency and scene structure for professional marketing and digital art.
View Details
Nana Banana Pro
Maintain perfect character consistency across diverse scenes and styles with advanced AI-powered image editing for creators, marketers, and storytellers.
View Details
Kling 4.0
Transform text and images into cinematic 1080p videos with multi-shot storytelling, character consistency, and native lip-synced audio for professional creators.
View Details
AI Seedance
Generate 15-second cinematic 2K videos with physics-based audio and multi-shot narratives from text or images. Ideal for creators and marketing teams.
View Details
Mistrezz.AI
Engage in immersive NSFW roleplay and ASMR voice sessions with adaptive AI companions designed for structured escalation, fantasy scenarios, and personal connection.
View Details
Seedance 3.0
Transform text prompts or static images into professional 1080p cinematic videos. Perfect for creators and marketers seeking high-quality, physics-aware AI motion.
View Details
Seedance 3.0
Transform text descriptions into cinematic 4K videos instantly with ByteDance's advanced AI, offering professional-grade visuals for creators and marketing teams.
View Details
Seedance 2.0
Generate broadcast-quality 4K videos from simple text prompts with precise text rendering, high-fidelity visuals, and batch processing for content creators.
View Details
BeatViz
Create professional, rhythm-synced music videos instantly with AI-powered visual generation, ideal for independent artists, social media creators, and marketers.
View Details
Seedance 2.0
Generate cinematic 1080p videos from text or images using advanced motion synthesis and multi-shot storytelling for marketing, social media, and creators.
View Details